Story perspectives

Obesity Drug Battle: Eli Lilly vs. Novo Nordisk in India

12/26/2025

36 8

Summary

Story summary

Eli Lilly and Novo Nordisk are competing for dominance in India's obesity drug market before cheaper generics arrive in March 2026.
Novo Nordisk emphasizes price cuts and rapid launches, while Eli Lilly benefits from its early market entry.
Both companies are enhancing outreach to doctors, advertising, and forming partnerships with local clinics and drug manufacturers.
By 2050, India is expected to have a significant overweight population, making it a crucial market for obesity drugs.
Analysts estimate the global obesity drug market could reach $150 billion annually by the decade's end, with India's market potentially exceeding $1 billion within two years.

1 of 1

Story summary

Eli Lilly and Novo Nordisk are competing for dominance in India's obesity drug market before cheaper generics arrive in March 2026.
Novo Nordisk emphasizes price cuts and rapid launches, while Eli Lilly benefits from its early market entry.
Both companies are enhancing outreach to doctors, advertising, and forming partnerships with local clinics and drug manufacturers.
By 2050, India is expected to have a significant overweight population, making it a crucial market for obesity drugs.
Analysts estimate the global obesity drug market could reach $150 billion annually by the decade's end, with India's market potentially exceeding $1 billion within two years.